NYSE:CRMD
CorMedix Inc Stock News
$5.33
-0.120 (-2.20%)
At Close: Apr 24, 2024
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
12:54pm, Monday, 15'th Apr 2024
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
10:55am, Thursday, 11'th Apr 2024
The mean of analysts' price targets for CorMedix (CRMD) points to a 146.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
CorMedix (CRMD) Q4 2023 Earnings Call Transcript
11:17am, Tuesday, 12'th Mar 2024
CorMedix Inc. (NASDAQ:CRMD ) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President, Chief Financia
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
08:30am, Wednesday, 06'th Mar 2024
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
U.S. FDA approves CorMedix's antimicrobial drug
10:11am, Wednesday, 15'th Nov 2023
The U.S. Food and Drug Administration (FDA) on Wednesday approved CorMedix's antimicrobial drug that aims to reduce catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, th
CorMedix Inc. (CRMD) Q3 2023 Earnings Call Transcript
09:55pm, Tuesday, 14'th Nov 2023
CorMedix Inc. (NASDAQ:CRMD ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors Joseph Todisco - CEO Matt David - EVP and CFO Phoebe Mou
CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
08:30am, Thursday, 02'nd Nov 2023
BERKELEY HEIGHTS, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
08:30am, Tuesday, 26'th Sep 2023
BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
Why Shares of CorMedix Are Slumping Thursday
12:22pm, Thursday, 29'th Jun 2023
CorMedix's lead therapy is DefenCath. The company is awaiting word from the FDA on the therapy's approval.
Why Is Cormedix (CRMD) Stock Down 23% Today?
09:30am, Thursday, 29'th Jun 2023
Cormedix (NASDAQ: CRMD ) stock is falling hard on Thursday after the company priced a public offering of its shares. That public offering has the company selling 7.5 million shares of CRMD stock at a
Cormedix Inc. To Present At The Jefferies Healthcare Conference
08:30am, Tuesday, 30'th May 2023
BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and
CorMedix Inc. (CRMD) Q1 2023 Earnings Call Transcript
07:27pm, Monday, 15'th May 2023
CorMedix Inc. (NASDAQ:CRMD ) Q1 2023 Earnings Call May 15, 2023 4:30 PM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
08:30am, Wednesday, 03'rd May 2023
BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and
7 Small-Cap Biotech Stocks with Massive Potential
06:36pm, Thursday, 27'th Apr 2023
While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappo
Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
11:27am, Thursday, 27'th Apr 2023
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisi